SNAP-25 in Serum Is Carried by Exosomes of Neuronal Origin and Is a Potential Biomarker of Alzheimer’s Disease

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A loss of synaptic density and connectivity is observed in multiple brain regions of Alzheimer’s disease (AD) patients, resulting in a reduced expression of synaptic proteins such as SNAP-25 (synaptosomal-associated-protein-25). SNAP-25 alterations thus could be an index of the degree of synaptic degeneration in the central nervous system (CNS). We isolated from serum of both AD patients and healthy controls (HC) a population of neuron-derived exosomes (NDEs) and measured the concentrations of SNAP-25 contained in such NDEs. The levels of SNAP-25 carried by NDEs were reduced in AD patients (mean 459.05 ng/ml, SD 146.35 ng/ml) compared to HC (mean 686.42 ng/ml, SD 204.08 ng/ml) (p < 0.001). As a further confirmation of these results, ROC (receiver operating characteristic) analyses indicated that the level of SNAP-25 carried by NDEs has the power to discriminate between AD and HC (AUC = 0.826, sensitivity = 87.5%, specificity = 70.6%, p < 0.0001, cut-off value 587.07 ng/ml). Notably, a correlation between the levels of SNAP-25 carried by NDEs and levels and cognitive status measured by MMSE score (r = 0.465, 95% CI 0.11 to 0.714, p = 0.01) was detected. This is the first report of SNAP-25 measurement in serum. These data suggest that NDE-carried SNAP-25 could be an effective and accessible biomarker that reflects synapses integrity in the brain.

Original languageEnglish
Pages (from-to)5792-5798
Number of pages7
JournalMolecular Neurobiology
Volume56
Issue number8
DOIs
Publication statusPublished - Aug 15 2019

Fingerprint

Synaptosomal-Associated Protein 25
Exosomes
Alzheimer Disease
Biomarkers
Serum
Neurons
Brain
ROC Curve
Synapses
Area Under Curve
Central Nervous System
Sensitivity and Specificity

Keywords

  • Alzheimer’s disease
  • Biomarker
  • Exosomes
  • Peripheral
  • SNAP-25
  • Synaptic proteins

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{7f2591413ac74816abe80d5439d8405c,
title = "SNAP-25 in Serum Is Carried by Exosomes of Neuronal Origin and Is a Potential Biomarker of Alzheimer’s Disease",
abstract = "A loss of synaptic density and connectivity is observed in multiple brain regions of Alzheimer’s disease (AD) patients, resulting in a reduced expression of synaptic proteins such as SNAP-25 (synaptosomal-associated-protein-25). SNAP-25 alterations thus could be an index of the degree of synaptic degeneration in the central nervous system (CNS). We isolated from serum of both AD patients and healthy controls (HC) a population of neuron-derived exosomes (NDEs) and measured the concentrations of SNAP-25 contained in such NDEs. The levels of SNAP-25 carried by NDEs were reduced in AD patients (mean 459.05 ng/ml, SD 146.35 ng/ml) compared to HC (mean 686.42 ng/ml, SD 204.08 ng/ml) (p < 0.001). As a further confirmation of these results, ROC (receiver operating characteristic) analyses indicated that the level of SNAP-25 carried by NDEs has the power to discriminate between AD and HC (AUC = 0.826, sensitivity = 87.5{\%}, specificity = 70.6{\%}, p < 0.0001, cut-off value 587.07 ng/ml). Notably, a correlation between the levels of SNAP-25 carried by NDEs and levels and cognitive status measured by MMSE score (r = 0.465, 95{\%} CI 0.11 to 0.714, p = 0.01) was detected. This is the first report of SNAP-25 measurement in serum. These data suggest that NDE-carried SNAP-25 could be an effective and accessible biomarker that reflects synapses integrity in the brain.",
keywords = "Alzheimer’s disease, Biomarker, Exosomes, Peripheral, SNAP-25, Synaptic proteins",
author = "Cristina Agliardi and Guerini, {Franca R.} and Milena Zanzottera and Anna Bianchi and Raffaello Nemni and Mario Clerici",
year = "2019",
month = "8",
day = "15",
doi = "10.1007/s12035-019-1501-x",
language = "English",
volume = "56",
pages = "5792--5798",
journal = "Molecular Neurobiology",
issn = "0893-7648",
publisher = "Humana Press Inc.",
number = "8",

}

TY - JOUR

T1 - SNAP-25 in Serum Is Carried by Exosomes of Neuronal Origin and Is a Potential Biomarker of Alzheimer’s Disease

AU - Agliardi, Cristina

AU - Guerini, Franca R.

AU - Zanzottera, Milena

AU - Bianchi, Anna

AU - Nemni, Raffaello

AU - Clerici, Mario

PY - 2019/8/15

Y1 - 2019/8/15

N2 - A loss of synaptic density and connectivity is observed in multiple brain regions of Alzheimer’s disease (AD) patients, resulting in a reduced expression of synaptic proteins such as SNAP-25 (synaptosomal-associated-protein-25). SNAP-25 alterations thus could be an index of the degree of synaptic degeneration in the central nervous system (CNS). We isolated from serum of both AD patients and healthy controls (HC) a population of neuron-derived exosomes (NDEs) and measured the concentrations of SNAP-25 contained in such NDEs. The levels of SNAP-25 carried by NDEs were reduced in AD patients (mean 459.05 ng/ml, SD 146.35 ng/ml) compared to HC (mean 686.42 ng/ml, SD 204.08 ng/ml) (p < 0.001). As a further confirmation of these results, ROC (receiver operating characteristic) analyses indicated that the level of SNAP-25 carried by NDEs has the power to discriminate between AD and HC (AUC = 0.826, sensitivity = 87.5%, specificity = 70.6%, p < 0.0001, cut-off value 587.07 ng/ml). Notably, a correlation between the levels of SNAP-25 carried by NDEs and levels and cognitive status measured by MMSE score (r = 0.465, 95% CI 0.11 to 0.714, p = 0.01) was detected. This is the first report of SNAP-25 measurement in serum. These data suggest that NDE-carried SNAP-25 could be an effective and accessible biomarker that reflects synapses integrity in the brain.

AB - A loss of synaptic density and connectivity is observed in multiple brain regions of Alzheimer’s disease (AD) patients, resulting in a reduced expression of synaptic proteins such as SNAP-25 (synaptosomal-associated-protein-25). SNAP-25 alterations thus could be an index of the degree of synaptic degeneration in the central nervous system (CNS). We isolated from serum of both AD patients and healthy controls (HC) a population of neuron-derived exosomes (NDEs) and measured the concentrations of SNAP-25 contained in such NDEs. The levels of SNAP-25 carried by NDEs were reduced in AD patients (mean 459.05 ng/ml, SD 146.35 ng/ml) compared to HC (mean 686.42 ng/ml, SD 204.08 ng/ml) (p < 0.001). As a further confirmation of these results, ROC (receiver operating characteristic) analyses indicated that the level of SNAP-25 carried by NDEs has the power to discriminate between AD and HC (AUC = 0.826, sensitivity = 87.5%, specificity = 70.6%, p < 0.0001, cut-off value 587.07 ng/ml). Notably, a correlation between the levels of SNAP-25 carried by NDEs and levels and cognitive status measured by MMSE score (r = 0.465, 95% CI 0.11 to 0.714, p = 0.01) was detected. This is the first report of SNAP-25 measurement in serum. These data suggest that NDE-carried SNAP-25 could be an effective and accessible biomarker that reflects synapses integrity in the brain.

KW - Alzheimer’s disease

KW - Biomarker

KW - Exosomes

KW - Peripheral

KW - SNAP-25

KW - Synaptic proteins

UR - http://www.scopus.com/inward/record.url?scp=85068774685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068774685&partnerID=8YFLogxK

U2 - 10.1007/s12035-019-1501-x

DO - 10.1007/s12035-019-1501-x

M3 - Article

AN - SCOPUS:85068774685

VL - 56

SP - 5792

EP - 5798

JO - Molecular Neurobiology

JF - Molecular Neurobiology

SN - 0893-7648

IS - 8

ER -